Click on image above to view full version

We, PT Pyridam Farma Tbk., (the “Company”), would like to notify the postponement on the Public Expose that is originally planned to be electronically held on Wednesday, July 20, 2022 to become as follows:   Day/Date       : Thursday, July 28, 2022 Time               : 3.30 – 4.30 p.m. Jakarta time Media             : Zoom Video Webinar Application Agenda          : Presentation of the Company's Performance for the 2022 Fiscal Year   The procedure for registering participants of the Public Expose is as follows:   All participants shall register via https://pubex.pyfa.co.id/ no later than Wednesday, July 27, 2022

The Board of Directors of PT Pyridam Farma Tbk., (hereinafter referred to as the “Company”) domiciled in South Jakarta, hereby invites the shareholders to attend the Electronic Public Expose (“Public Expose”) of the Company which will be held on:   Day/Date       : Wednesday, July 20, 2022 Time               : 3.30 – 4.30 p.m. Jakarta time Media             : Zoom Video Webinar Application Agenda          : Presentation of the Company's Performance for the 2022 Fiscal Year   The procedure for registering participants of the Public Expose is as follows:   All participants shall register via https://pubex.pyfa.co.id/ no later

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and Annex to Regulation I-E of Decree of the Board of Directors of PT Bursa Efek No. Kep. 00015/BEI/01-2021 on Obligations of Information Submission, we, PT Pyridam Farma Tbk (“Company”) hereby inform that the Company intends to cooperate with PT Mundipharma Healthcare Indonesia (“Mundipharma”), an Indonesian company that holds the trademark of Betadine products (“Products”) in Indonesia (“Cooperation”).   In connection with the Cooperation, the Company and Mundipharma has signed a Marketing

Wednesday, March 2nd 2022 Click to View PDF File

Click here to View PDF File

Click here to view PDF File

Click image to see full document  

Referring to (i) Financial Service Authority (“FSA”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company, (ii) Annex to Regulation I-E of Decree of the Board of Directors of PT Bursa Efek No. KEP-00015/BEI/01-2021 on Obligations of Information Submission, and (iii) Part VII Point 3 of Annex to FSA Letter No. S-1780/PM.222/2021 dated November 3rd, 2021 on Changes and/or Additional Information on the Proposed Material Transaction of PT Pyridam Farma Tbk in connection with the obligation to report the results of the implementation of material

Click image to see full PDF

Press Release from KRI Report of Annual Rating (PYFA)

Based on the Decree of the Board of Directors of PT Pyridam Farma Tbk. (the “Company”) No. 129/PYFA-DIR/E/XI/2021 dated 19 November 2021 concerning the Dismissal and Appointment of the Head and/or Member of the Internal Audit Unit, and with reference to the prevailing laws and regulations, including Financial Services Authority (Otoritas Jasa Keuangan or OJK) Regulation No. 56/POJK.04/2015 concerning the Formation and Guidelines in Preparing the Internal Audit Unit Charter, we hereby inform you that there has been a change in the Head of the Company's Internal Audit Unit which

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company, we, PT Pyridam Farma Tbk (“Company”) hereby inform that the Company and its affiliate intends to (i) purchase 27,385 shares or equivalent to 100% (one hundred percent) of the total issued and paid-up capital in PT Holi Pharma (“HP”) from HP’s existing shareholders, namely Erik Darius Mardiwidyo and Murtiati (the “Sellers”), along with a Company’s affiliate ; and (ii) subscribe new shares to be issued by HP (“Proposed Acquisition”), which

PUBLIC EXPOSE ANNOUNCEMENT PT PYRIDAM FARMA TBK   The Board Directors of PT Pyridam Farma Tbk., domiciled in South Jakarta (hereinafter referred to as the “Company”) hereby invites the shareholders to attend the Electronic Public Expose (“Public Expose”) of the company which will be held on:   Day/Date                     : Wednesday, August 25th 2021 Waktu                          : 4.00 – 5.00 p.m. Jakarta time Media                           : Zoom Video Webinar Application Agenda                       : Exposure of the Company's Performance for the 2021 Fiscal Year   The procedure for registering participants of the Public Expose is as follows: All participants shall register via https://pubex.pyfa.co.id/

Click link below: Report of Fund Utilization -  Obligasi Pyridam Farma I 2020-Juni 2021 Report of Fund Utilization -  Obligasi Pyridam Farma I Desember 2021 Report of Fund Utilization - Pyridam Farma Sustainable Bond I Phase I 2022 - June 2022

Referring to Financial Service Authority (“OJK”) Regulation No. 17/POJK.04/2020 on Material Transaction and Business Activity Changes (“POJK No. 17/2020”), OJK Regulation No. 31/POJK.04/2015 on Disclosure of Information or Material Facts by Issuers or Public Companies and Indonesia Stock Exchange Regulation No. I-E as attachment to the decision of the board of the Indonesia Stock Exchange No. KEP-00015/BEI/01-2021 on the Obligations of Information Submission, we hereby submit an Information Report or Material Facts related to Material Transactions (as referred to in POJK 17/2020) conducted by PT Pyridam Farma Tbk. (the “Company”),

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company, we, PT Pyridam Farma Tbk. (“Company”) hereby inform: Company is the 99.00% shareholder from the total issued and paid-up capital of PT Pyfa Investama Medika (“PIM”), in which PIM’s financial statements are consolidated with the Company. As a follow up of our report in Information Disclosure No. 021/PYFA-CS/IV/2021 dated 22 April 2021 (“KI 021/2021”), Company reports that PIM has completed the transaction of subscription of new shares that results subscribe new

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company, we, PT Pyridam Farma Tbk. (“Company”) hereby inform that the Company intends to cooperate with LG International Corp. (“LGI”), a Korean company engaged in trade and investment, to carry out marketing and sales of LGI and/or its affiliates’ health products (“Product”) in Indonesia (“Cooperation”). In connection with the Cooperation, the Company and LGI has signed a Cooperation Agreement on 28 April 2021 (“Cooperation Agreement”) Both parties agree to work on number

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company, we, PT Pyridam Farma Tbk. (“Company”) hereby inform that the Company is the 99.00% shareholder from the total issued and paid-up capital of PT Pyfa Investama Medika (“PIM”), in which PIM’s financial statements are consolidated with the Company. PIM intends to subscribe new shares which will result PIM in having minority shareholding in Fullerton Health Indonesia Group an integrated healthcare company in Indonesia, offering a one-stop service to corporate clients

Referring to Financial Service Authority (“OJK”) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and the Decision of the Board of Directors of the Indonesia No. Kep. 00015/BEI/01-2021 on the Amendment of Regulation No. I-E concerning Obligations to Submit Information, we, PT Pyridam Farma Tbk. (“Company”) hereby inform that on 22 and 23 March 2021, 4 (four) subsidiaries have been established as follow: 1. PT Mega Inter Distrindo Pursuant to Deed of Establishment No. 07 , dated 23 March 2021 , made before Mudita Chitta Odang,

Referring to Financial Service Authority (OJK) Regulation No. 31/POJK.04/2015 on Information Disclosure of Material Facts by Issuer of Public Company and the Decision of the Board of Directors of the Indonesia No. 00015/BEI/01-2021 on the Amendment of Regulation No.  I-E concerning Obligations to Submit Information, we, PT Pyridam Farma Tbk. (“Company”) hereby inform that on 22 February 2021, to support its business activities, the Company has opened a representative office in South Korea based on its Certificate of Business Registration No. 2109-885-5994-106, dated 24 February 2021, issued by the Head

Prospectus of Pyridam Farma Bond I 2020

Additional Information Abridged Prospectus_04012021

Abridged Prospectus of Pyridam Farma Bond I (p.1) Abridged Prospectus of Pyridam Farma Bond I (p.2)

In commemoration of the 44th anniversary of PT Pyridam Farma Tbk. (the “Company”), the Company hereby announces the change of the Company’s logo to become as follows: The Company’s logo is changed pursuant with Decree of the Board of Directors of the Company No. 103/B/PYFA-I/XI/2020 regarding Change of Company’s Logo dated 27 November 2020. The change is effective as of 27 November 2020. The change of the Company's logo is a part of the Company's effort to keep up with the trend by instilling a more modern identity to be always adaptive

Pursuant to Financial Service Authority Regulation No. 35/POJK.04/2014 regarding Corporate Secretary of Issuer or Public Company and based on Decree of the Board of Directors of PT Pyridam Farma Tbk. (the “Company”) No. 06/B/PYFA-I/XI/2020 dated 5 November 2020 regarding the Termination and Appointment of Corporate Secretary, we hereby announce the change of the Corporate Secretary of the Company which has been effective on 5 November 2020, with the following details:   New Corporate Secretary Previous Corporate Secretary Name Nadia Miranty Verdiana Ryan Arvin Sutikno Address Sinarmas MSIG Tower, Lantai 12 Jl. Jendral Sudirman Kav. 21, RT10/RW1, Kuningan, Karet, Kec. Setiabudi, Jakarta

Report of the Mandatory Tender Offer Result

The Board of Directors of PT Pyridam FarmaTbk (the “Company”) wishes to announce that the Company has on October 12, 2020 entered into a non-binding memorandum of understanding (“MOU”) with Vaxine Pty Ltd (“Vaxine”) to explore the commercialization and manufacture of Vaxine’s Covid-19 Vaccine candidate Covax-19™ in Indonesia (the “Proposed Partnership”). Covax-19™ is currently undergoing phase 1 trials in Australia. The MOU is subject to the Company and Vaxine (together, the “Parties”) entering into a definitive Commercial Agreement and a definitive Manufacturing Agreement (the “Definitive Agreements”). Jakarta, October 14, 2020 PT Pyridam Farma

Letter to OJK No. 08_18 Sep 2020_Investment in the Subsidiary

Information Disclosure MTO Pyridam Farma Advertisement Harian Ekonomi Neraca (KI MTO PYFA) Information Disclosure to OJK & IDX

Advertisement 2020-07-21-4 Letter to OJK & IDX No. 11_22 Jul 2020